Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07419295 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 590
- Enrollment target
NCT07419295 is a Phase 3 study that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 590 participants.
The verdict
NCT07419295, a Phase 3 study, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 590 participants
- Enrollment target
Study Summary
Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies.
Interventions
- BIOLOGICAL Sacituzumab tirumotecan
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG Vinflunine
- DRUG Rescue medications for sacituzumab tirumotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 590 participants |
| Start Date | 2026-04-23 |
| Est. Completion | 2030-04-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07419295
The ClinicalTrials.gov registry entry for NCT07419295 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 590 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Sacituzumab tirumotecan is the first listed.
NCT07419295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07419295 about?
NCT07419295 is a clinical study titled "A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)". Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial me...
What is the current status of trial NCT07419295?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 590 participants. The study started on 2026-04-23. Estimated completion is 2030-04-23.
What interventions are being tested in trial NCT07419295?
The interventions under investigation include: Sacituzumab tirumotecan (BIOLOGICAL), Docetaxel (DRUG), Paclitaxel (DRUG), Vinflunine (DRUG), Rescue medications for sacituzumab tirumotecan (DRUG).
Who is sponsoring clinical trial NCT07419295?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.